[Azlocillin in the treatment of pulmonary infections in patients with cystic fibrosis: plasma concentrations and therapeutic indications].
Azlocillin plasma concentrations have been studied in 10 cystic fibrosis patients suffering from chronic pulmonary infections with Pseudomonas aeruginosa. Patients were given single i.v. doses of 100 e 200 mg/kg body weight as intravenous infusion over 30 minutes. Azlocillin plasma levels have been assayed by a rapid, sensitive and precise high performance liquid chromatographic method. After the dose of 100 mg/kg body weight concentrations of azlocillin decreased below the therapeutic concentrations after three hours; dose of 200 mg/kg was followed by plasma concentrations in the therapeutically desirable range during the 6-8 hours study period. The pharmacokinetic analysis offers further evidence of the dose-dependent nature of azlocillin elimination. Higher dosage of 200 mg/kg body weight and monitoring of plasma drug levels are recommended in the therapy of patients with cystic fibrosis.
Rosselli
P
P
Dipartimento di Pediatria, Università di Firenze, Italia.
Marianelli
L
L
Valenza
T
T
Bartolozzi
G
G
D000293:Adolescent; D001390:Azlocillin / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000097:blood / Q000150:complications*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D008297:Male; D011552:Pseudomonas Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy
D001390:Azlocillin
L'azlocillina nel trattamento delle infezioni polmonari dei pazienti affetti da fibrosi cistica: concentrazioni plasmatiche e indicazioni terapeutiche.